載入...
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold
The constitutively active tyrosine kinase BCR-ABL is the underlying cause of chronic myeloid leukemia (CML). Current CML treatments rely on the long-term use of tyrosine kinase inhibitors (TKIs), which target the ATP binding site of BCR-ABL. Over the course of treatment, 20–30% of CML patients devel...
Na minha lista:
| 發表在: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4532999/ https://ncbi.nlm.nih.gov/pubmed/26264857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12974 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|